SCHEMBL25979754

SCHEMBL25979754

CCOC(=O)C1(C)CC(NNC(=O)OC(C)(C)C)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 4/20 0.36
TSHR P16473 1/20 0.36
GAA P10253 2/20 0.36
APLNR P35414 1/20 0.35
LMNA P02545 1/20 0.35
BTK Q06187 1/20 0.34
HCRTR2 O43614 1/20 0.34
CTSL P07711 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
BRD4 O60885 1/20 0.33
EPHX1 P07099 1/20 0.33
MAPT P10636 1/20 0.32
CPB2 Q96IY4 1/20 0.32
CTSS P25774 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17827143 0.80 MEN1 (0.37) KMT2AMEN1MAPK1ALDH1A1TSHR
SCHEMBL17048744 0.77 KMT2A (0.37) KMT2AMEN1MAPK1ALDH1A1TSHR
SCHEMBL17048742 0.77 KMT2A (0.37) KMT2AMEN1MAPK1ALDH1A1TSHR
SCHEMBL17048739 0.77 KMT2A (0.37) KMT2AMEN1MAPK1ALDH1A1TSHR
SCHEMBL23038833 0.77 MEN1 (0.45) KMT2AMEN1MAPK1GAAAPLNR
SCHEMBL25978289 0.77 MEN1 (0.45) KMT2AMEN1MAPK1GAAAPLNR
SCHEMBL25978287 0.77 MEN1 (0.45) KMT2AMEN1MAPK1GAAAPLNR
SCHEMBL17118117 0.76 MEN1 (0.44) KMT2AMEN1MAPK1ALDH1A1TSHR
SCHEMBL2329093 0.76 MEN1 (0.44) KMT2AMEN1MAPK1TSHRGAA
SCHEMBL25978825 0.75 MEN1 (0.50) KMT2AMEN1MAPK1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145599-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MRJA THERAPEUTICS, INC. 2025-05-08 US disclosed
WO-2023150663-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS RETUNE PHARMA INC. (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145599-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS IGF1R, IGFBP1, IGFBP2 KMT2A 3829/4885MEN1 248/4885MAPK1 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.